Table 1.

ARHGAP10-IgG/anti-Ca2 in the serum and CSF of 12 ARHGAP26-IgG/anti-Ca-positive patients

Patient	Sample	Days since onset	TBA Cerebellum	CBA ARHGAP26	End titres	CBA ARHGAP10	End titres
			Fluorescence signal intensity at screening dilution (1:10)	Fluorescence signal intensity at screening dilution (1:10)		Fluorescence signal intensity at screening dilution (1:10)
a. Serum samples
1	1	5	+  +	+  +  +  +  +	1:10,000	+  +  +  +  +	1:1000
	2	167	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	3	173	+  +  +	+  +  +  +	1:10,000	+  +  +  +	1:1000
	4	211	+  +  +	+  +  +  +  +	1:10,000	+  +  +  +  +	1:3200
	5	237	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	6	375	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	7	557	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	8	1160	+  +  +	+  +  +  +	nd	+  +  +  +	nd
	9	1252	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	10	1357	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	11	1469	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	12	1671	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	13	1959	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	14	2142	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	15	2330	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	16	2889	+  +  +	+  +  +  +  +	nd	+  +  +  +  +	nd
	17	3246	+  +  +	+  +  +  +  +	1:3200	+  +  +  +  +	1:1000
	18	3352	+  +  +	+  +  +  +	1:3200	+  +  +	1:1000
2	1	nd	+  +  +	+  +  +	1:1000	+	1:32
3	1	nd	+  +  +  +	+  +  +  +	1:320,000	+  +  +	1:32,000
4	1	nd	+  +  +	+  +  +  +  +	1:1,000,000	+  +  +  +  +	1:32,000
5	1	nd	+  +  +	+  +  +  +  +	1:1,000,000	+  +  +  +  +	1:32,000
6	1	nd	+	+  +	1:320	+	1:10
7	1	nd	+  +	+  +	1:20	+	1:10
8	1	nd	+  +  +  +	+  +	1:320	+  +	1:320
9	1	nd2	+  +	+  +	1:100	+	1:10
	2	nd2	+  +	+  +	1:100	–	–
	3	nd2	–	+  +  +	1:100	–	–
10	1	nd	+  +  +	+  +  +	1:3200	–	–
11	1	nd	+	+  +	1:32	–	–
12	1	nd	+  +  +  +	+  +  +  +	1:3200	+  +	1:100
b. CSF samples
1	1	5	+  +  +  +	+  +  +  +  +	1:2000	+  +  +  +	1:150
	2	167	+  +  +  +	+  +  +  +  +	nd	+  +  +  +	nd
2	1	nd3	+  +  +	+  +  +  +	1:140	+  +	1:10
	2	nd3	+  +	+  +  +  +	1:16	+  +	1:2
6	1	nd	–	+	1:1	–	–
10	1	nd	nd1	+  +	1:4	–	–

In addition, 101 control samples (32 × cerebellar ataxia of suspected autoimmune aetiology; 21 x other autoantibody-associated CNS disorders; 31 × multiple sclerosis; 7 × headache; 10 × healthy controls) were tested, including 81 serum samples and 20 CSF samples, 100 of which were negative for ARHGAP10-IgG/anti-Ca2 (1 control serum sample mildly positive: 1:10 positive; 1:32 equivocally positive); see Methods and Results for details. 

¹Insufficient material available

²Obtained over a period of 8 months; time since onset of neurological symptoms unknown

³Obtained over a period of 14 days; time since onset of neurological symptoms unknown.

nd = not done/no data